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Abstract
Interleukin IL-17 is a proinflammatory cytokine that has been implicated in the pathogenesis of various autoimmune
diseases. The single nucleotide polymorphism (SNP), rs2275913, in the promoter region of the IL-17 gene is associated with
susceptibility to ulcerative colitis. When we examined the impact of rs2275913 in a cohort consisting of 438 pairs of patients
and their unrelated donors transplanted through the Japan Marrow Donor Program, the donor IL-17 197A allele was found
to be associated with a higher risk of acute graft-versus-host disease (GVHD; hazard ratio [HR], 1.46; 95% confidence interval
[CI], 1.00 to 2.13; P=0.05). Next, we investigated the functional relevance of the rs2275913 SNP. In vitro stimulated T cells
from healthy individuals possessing the 197A allele produced significantly more IL-17 than those without the 197A allele. In
a gene reporter assay, the 197A allele construct induced higher luciferase activity than the 197G allele, and the difference
was higher in the presence of T cell receptor activation and was abrogated by cyclosporine treatment. Moreover, the 197A
allele displayed a higher affinity for the nuclear factor activated T cells (NFAT), a critical transcription factor involved in IL-17
regulation. These findings substantiate the functional relevance of the rs2275913 polymorphism and indicate that the
higher IL-17 secretion by individuals with the 197A allele likely accounts for their increased risk for acute GVHD and certain
autoimmune diseases.
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Introduction
Interleukin 17 (IL-17), also known as IL-17A, plays an im-
portant role in tissue inflammation, and is involved in the
pathophysiology of autoimmune diseases and organ allograft
rejection [1,2,3,4,5,6,7,8,9,10,11]. Moreover, several reports have
shown that Th17 cells and IL-17 have a significant impact on the
development of acute graft-versus-host disease (GVHD) in mouse
models [12,13,14,15,16,17]. The 197A allele, which is the result of
a single nucleotide polymorphism (SNP) rs2275913 (G197A) in the
promoter region of the IL-17 gene, has been reported to be
associated with the susceptibility to rheumatoid arthritis [18] and
ulcerative colitis [19]. In our previous study, we demonstrated that
the 197A allele was also implicated in the development of acute
GVHD in patients who underwent unrelated myeloablative bone
marrow transplantation (BMT) [20]. In the present study, we
extended this investigation to a validation cohort of patients who
received an unrelated BMT, including patients who underwent
reduced intensity transplantation.
Interestingly, the rs2275913 SNP is located within a binding
motif for the nuclear factor activated T cells (NFAT), which is
a critical regulator of the IL-17 promoter [21]. Therefore, it is
conceivable that the rs2275913 SNP exerts an effect on the
transcriptional regulation of IL-17. The present study shows that
allele 197A correlates with more efficient IL-17 secretion, and that
this resulted from its higher affinity for NFAT.
Materials and Methods
Patients
IL-17 genotyping was performed on 438 recipients with
hematological malignancies and their unrelated donors who
underwent BMT through the Japan Marrow Donor Program
(JMDP) with T-cell-replete marrow from HLA-A, -B, -C, -DRB1,
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and December 2007. The HLA genotypes of patients and donors
were determined by the Luminex microbead method as described
previously (Luminex 100 System; Luminex, Austin, TX) [22,23].
Although the Luminex microbead method does not provide
unambiguous HLA 4-digit typing for all genotypes, the JMDP has
confirmed that this method can identify all HLA alleles with
.0.1% frequency among the Japanese population [24].
None of the present patients had a history of any prior
transplantation. The final clinical survey of these patients was
completed by November 1, 2008. The diagnoses were acute
myeloid leukemia (AML) in 149 (34%), acute lymphoblastic
leukemia (ALL) in 109 (25%), myelodysplastic syndrome (MDS) in
78 (18%), malignant lymphoma (ML) in 55 (15%), chronic
myeloid leukemia in 42 (10%), and multiple myeloma (MM) in 5
(1%; Tables 1 and 2). The recipients were defined as having
standard risk disease if they had AML or ALL in the first complete
remission, ML in any complete remission, CML in any chronic
phase, or MDS. All others were designated as having high-risk
disease. The myeloid malignancies include AML, MDS and CML,
and the lymphoid malignancies included ALL, ML and MM.
Cyclosporine- or tacrolimus-based regimens were used in all
patients for GVHD prophylaxis, and anti-T cell therapy, such as
anti-thymocyte globulin and ex vivo T cell depletion were not in
any of the patients. All patients and donors gave their written
informed consent at the time of transplantation to participate in
molecular studies of this nature according to the declaration of
Helsinki. This project was approved by the Institutional Review
Board of Kanazawa University Graduate School of Medicine and
the JMDP.
IL-17 genotyping
Genotyping of IL-17 was performed using the TaqMan-Allelic
discrimination method with the Assay ID C__15879983_10
(Applied Biosystems) as described in a previous report [20].
Cells and reagents
Primers and oligonucleotides were obtained from Hokkaido
Science Systems (Sapporo, Japan). The GST-NFATc1 construct
[25] was a generous gift from Dr Shoichiro Miyatake. An NFATc
binding consensus oligonucleotide (sc-2577) was purchased from
Santa Cruz Biotechnology (Santa Cruz, California).
Table 1. The donor and recipient characteristics (first part).
Variable No. Ratio
No. of cases 438
Recipient age, years
Median 39
Range 1–70
Donor age, years
Median 35
Range 20–57
Year of transplant
Median 2003
Range 1993–2007
Recipient IL-17 genotype
G/G 180 41%
A/G 200 46%
A/A 58 13%
Donor IL-17 genotype
G/G 166 38%
A/G 200 46%
A/A 66 15%
Recipient sex
Male 281 64%
Female 157 36%
Donor sex
Male 296 68%
Female 142 32%
Donor/recipient sex
Sex matched 299 68%
Female/male 62 14%
Male/female 77 18%
doi:10.1371/journal.pone.0026229.t001
Table 2. Donor and recipient characteristics (second part).
Variable No. Ratio
Disease
Acute myeloid leukemia 149 34%
Acute lymphoblastic leukemia 109 25%
Myelodysplastic syndrome 78 18%
Malignant lymphoma 55 13%
Chronic myeloid leukemia 42 10%
Multiple myeloma 5 1%
Disease stage
Standard risk 178 41%
High risk 260 59%
ABO matching
Major or/and minor mismatch 160 37%
Major mismatch 91 21%
Minor mismatch 86 20%
Bidirectional 17 4%
Missing 8 2%
Conditioning regimen
Myeloablative 325 74%
Reduced intensity 113 26%
With total body irradiation 333 76%
Pretransplant CMV serostatus
CMV positive recipient 324 74%
Missing 40 9%
GVHD prophylaxis
With cyclosporine 190 43%
With tacrolimus 248 57%
TNC, 610
8 per kg
Median 4.6
Range 0.1–316.8
Abbreviations: TNC: total nucleated cell count harvested.
doi:10.1371/journal.pone.0026229.t002
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Heparinized blood samples were collected from 54 healthy
Japanese volunteers. The ages of the subjects (30 males and 24
females) ranged from 20 and 56 years (median, 32 years).
Peripheral blood mononuclear cells (PBMCs) were isolated using
a Ficoll-Hypaque gradient (Pharmacia Biotech, Uppsala, Sweden)
and were induced to secrete IL-17 by culturing the PBMCs (10
6/
well) in 24 well plates for 48 hours in RPMI 1640 supplemented
with 10% fetal bovine serum in the presence or absence of 5 mg/
ml phytohemagglutinin (PHA; Sigma) at 37uCi n5 %C O 2.I n
some experiments, PBMCs (10
6 cells/well) were seeded in 48 well
plates coated with anti-CD3 (2 mg/ml) and anti-CD28 (1 mg/ml)
monoclonal antibodies (Miltenyi Biotec, Gladbach, Germany) to
activate T cells selectively, and then were cultured for 48 hrs. The
concentrations of IL-17 in collected supernatants were measured
by an enzyme-linked immunosorbent assay (ELISA; Mabtech,
Nacka Strand, Sweden). For some functional assays, PBMCs
(6610
6 cells/well) were cultured in six well plates for 72 hrs in the
presence of 5 mg /ml of PHA and 100 U/ml of IL-2, and are
hereafter designated as PHA-PBMCs.
Quantitative RT- PCR
RNA was extracted from resting or PHA-activated PBMCs using
the high pure RNA isolation kit (Roche). Reverse transcription
was carried out with the PrimeScript RT reagent/gDNA eraser kit
(Catalog RR047A, Takara). Quantitative real time PCR was
performed in a StepOne Plus PCR system (Applies Biosystems)
using the SYBR premix ExTaq perfect Real Time (Catalog
RR041A, Takara) with the IL-17 primers described previously
[26] and a set of primers for human GAPDH (Takara). The relative
IL-17 mRNA levels normalized to GAPDH were calculated by the
DDCTmethodusingtherelativeexpressionfunctionincludedinthe
StepOne v2.2 software program. The specificity of the PCR
products was monitored by a melting curves analysis.
Luciferase assay
The promoter region of the IL-17 gene was amplified from
the genomic DNA of individuals homozygous for the rs2275913
SNP (A197A or G197G) by polymerase chain reaction (PCR)
with forward 59-ACGCGTGGATCTCAGGACAAACAGGTTC-
39 and reverse 59-AAGCTTGACTCACCACCAATGAGGT-
CTT-39 primers as described previously [21]. The resultant
fragments IL-17/197A or IL-17/197G were subcloned into the
pGL3-enhancer vector at the MluI and HindIII sites (Promega,
Madison, WI) to generate pGL3-197A-enhancer or pGL3-197G-
enhancer constructs. The fragments were inserted with the same
orientation, and their nucleotide sequences were confirmed by DNA
sequencing. Equimolar amounts of the following reporter plasmids:
pGL3-enhancer, pGL3-197A-enhancer and pGL3-197G enhancer
designated thereafter as pGL3-Luc, IL-17/A-Luc IL-17/G-Luc
respectively, were transfected into PHA-PBMCs using the Exfect
transfection reagent following the manufacturer instructions (Takara
Bio, Japan). To control for differences in the transfection efficiency,
cells were cotransfected with a renilla reporter plasmid, pRL-TK. In
some experiments, the cells were treated with anti-CD3 and anti-
CD28 mAbs or with Cyclosporine A (CsA) 24 hours after the
transfection, and were cultured for other 24 hours. The activity of
both luciferase and renilla in the transfected cells was measured with
the Dual Luciferase Reporter Assay System (Promega).
Electrophoresis motility shift assay (EMSA)
Double stranded IL-17 probes, including those harboring
G197A, were generated by annealing the following oligonucleo-
tides to their complementary oligonucleotides: CAT TTT CCT
TCA GAA GAA GAG ATT CTT CTA (197A allele) and CAT
TTT CCT TCA GAA GGA GAG ATT CTT CTA (197G allele).
These oligomers encompass nucleotides 2180 to 2210 upstream
of the transcriptional start site, based on data in the human
genomic DNA Gene bank accession number AY460616.1. Before
annealing, both complementary oligonucleotides were separately
biotin-labeled at their 39 ends, using the 39 end DNA labeling kit
(Thermo Fisher Scientific, Suwanee, USA) following the manu-
facturer’s recommendations. Nuclear extracts from PHA-PBMCs
were prepared using a nuclear extraction kit (Thermo Fisher
Scientific). The DNA/protein binding assay was performed with
10 mg of nuclear extracts using the Light Shift Chemiluminescent
EMSA kit (Thermo Fisher Scientific) according to the manufac-
turer’s recommendations with minor modifications as follows: In
the DNA/NFAT recombinant protein assay 0.5% bovine serum
albumin was included in the binding reaction and purified GST-
NFAT-recombinant proteins were desalted using Zeba spin
desalting columns (Pierce). The DNA/protein complexes were
detected by streptavidin peroxidase and visualized in a Lumines-
cent Image Analyzer LAS-4000 (Fujifilm, Tokyo, Japan).
Data management and statistical analysis
The data were collected by the JMDP using a standardized
report form. Follow-up reports were submitted at 100 days, 1 year
and annually after transplantation. The pre-transplant cytomeg-
alovirus (CMV) serostatus was routinely tested for only patients,
but not the donors. Engraftment was confirmed by an absolute
neutrophil count of more than 0.5610
9/L for at least 3
consecutive days. After collecting the data, acute and chronic
GVHD were diagnosed and graded based on the classically
defined criteria [27,28], namely, acute GVHD develops within the
first 100 days post-transplant while the manifestation of GVHD
occurring after day 100 is classified as chronic GVHD. Data using
the updated criteria for assessment of GVHD [29,30] were not
available in our cohort. The overall survival (OS) was defined as
the number of days from transplantation to death from any cause.
Disease relapse was defined as the number of days from
transplantation to disease relapse. Transplant-related mortality
(TRM) was defined as death without relapse. Any patients who
were alive at the last-follow-up date were censored. The data
about the causative microbes of infections and postmortem
changes in the cause of death, as well as the data on supportive
care, including prophylaxis for infections and therapy for GVHD,
which were given on an institutional basis, were not available for
this cohort.
The analysis was performed using the Excel 2007 software
program (Microsoft Corp, Redmond, WA, USA) and modified R
(The R Foundation for Statistical Computing, Perugia, Italy)
software programs [31,32], as described in a previous report
[33,34]. The probability of OS was calculated using the Kaplan-
Meier method and compared using the log-rank test. The
probabilities of TRM, disease relapse, acute GVHD, chronic
GVHD, and engraftment were compared using the Grey test [35]
and analyzed using a cumulative incidence analysis [31], while
considering relapse, death without disease relapse, death without
acute GVHD, death without chronic GVHD, and death without
engraftment as respective competing risks. The variables included
the recipient age at the time of transplantation, sex, pretransplant
CMV serostatus, disease characteristics (disease type, disease
lineage and disease risk at transplantation), donor characteristics
(age, sex, sex compatibility, and ABO compatibility), transplant
characteristics (conventional or reduced-intensity conditioning
[36], total body irradiation-containing regimen, tacrolimus versus
Functional IL-17 Polymorphism in Unrelated BMT
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weight [TNC]), and the year of transplantation. The median was
used as the cutoff point for continuous variables. The chi-square
test and the Mann-Whitney U test were used to compare the two
groups. The Hardy-Weinberg equilibrium for the IL-17 gene
polymorphism was determined using the Haploview software
program [37].
Multivariate Cox models were used to evaluate the hazard ratio
associated with the IL-17 polymorphism. The covariates found to
be P#0.10 according to univariate analyses were used to adjust the
hazard ratio.
For both the univariate and multivariate analyses, the P values
were two sided, and the outcomes were considered to be
significant for P#0.05.
Results
Transplant outcome according to the IL-17 genotype
The genotype frequencies of 197G/G, 197A/G and 197A/A
were 41%, 46% and 13% in recipients, and 38%, 46% and 15%
in donors. These were similar to previous reports [18,38], and
were in accord with the Hardy-Weinberg equilibrium (P=0.88).
The transplant outcomes according to the IL-17 genotype are
summarized in Table 3. The presence of the 197A allele in the
197A/G or 197A/A genotype in the donor was associated with a
significantly higher incidence of grades II to IV acute GVHD
(38% vs. 27%, P=0.03; Fig. 1), while no significant differences
between the 197A/G genotype and the 197A/A genotype in the
recipient were seen in the incidence of grades II to IV acute
GVHD (38% vs. 36%, P=0.78). The acute GVHD-related
mortality did not differ between the donor 197A/G or 197A/A
genotypes and the donor 197G/G genotype (2% vs. 2%, P=0.83).
All of the factors found to be significant in the univariate
analyses were included in the model. The 197A/G or 197A/A
genotype in donors remained statistically significant in the
multivariate analyses for the development of grades II to IV acute
GVHD (Table 4). The 197A/G or 197A/A genotype in the
donor resulted in a higher incidence of grades II to IV acute
GVHD (hazard ratio [HR], 1.46; 95% confidence interval [CI],
1.00 to 2.13; P=0.05) even when adjusted for the other factors in
the models. The IL-17 genotype showed no significant effects on
the OS, TRM or relapse (Table 5).
The impact of the rs2275913 SNP on the secretion of
IL-17
To substantiate the biological significance of the rs2275913
SNP, we first examined whether the different genotypes correlated
with IL-17 secretion. PBMCs from a total of 54 healthy individuals
(197G/G in 24, 197A/G in 24 and 197A/A in 6) were stimulated
in vitro with PHA and the levels of secreted IL-17 were determined
by ELISA. As shown in Fig. 2A, the 197A allele positive (197A/G
or 197A/A genotype) PBMCs secreted significantly higher levels of
IL-17 than the 197A allele negative cells (197G/G genotype).
Similar results were obtained when T cells were selectively
stimulated with anti-CD3 and anti-CD28 mAbs (data not shown).
The quantitative RT-PCR analysis showed that PHA-stimulated
PBMCs from donors harboring the 197A allele had a significantly
higher IL-17 mRNA level than those from 197A allele negative
donors (Fig. 2B). Of note, the IL-17 mRNA levels in unstimulated
cells were very low, irrespective of 197A allele positivity, and
resulted in no differences between the two groups (data not
shown). Together, these results suggested that the sequence variant
rs2275913 influences the response of the IL-17 gene promoter to
factors released in response to T cell activation, thus leading to a
differential IL-17 production.
Figure 1. The estimated cumulative incidence curve of grades
II–IV acute GVHD according to the donor IL-17 genotype. The
solid line represents the donor 197A/G or A/A genotype, and the
dashed line represents the donor 197G/G genotype.
doi:10.1371/journal.pone.0026229.g001
Table 3. The results of the univariate analysis of the association of IL-17 polymorphisms with the clinical outcomes after
transplantation.
Variable No.
5-year
OS P
5-year
TRM P
5-year
relapse P
II–IV acute
GVHD P
Chronic
GVHD P
Recipient IL-17 genotype
G/G 180 41% 29% 37% 35% 41%
A/G or A/A 258 50% 0.59 28% 0.48 30% 0.10 30% 0.21 40% 0.78
Donor IL-17 genotype
G/G 166 50% 29% 31% 27% 37%
A/G or A/A 272 43% 0.22 28% 0.71 33% 0.77 38% 0.03 42% 0.18
doi:10.1371/journal.pone.0026229.t003
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gene promoter region
To address the functional significance of the rs2275913 SNP,
reporter gene constructs containing the 197A and 197G alleles
were prepared and used to transfect PHA-PBMCs. The results
revealed that the insertion of the IL-17 promoter fragment
consistently resulted in an augmentation of the luciferase activity
compared with the construct without the fragments, however, the
cells transfected with the IL-17/A-Luc construct had significantly
higher luciferase activity than cells transfected with the IL-17/G-
Luc construct (Fig. 3A). The differences in luciferase expression
induced by these two constructs were more evident when the
transfected cells were treated with anti-CD3 and anti-CD28 mAbs
(Fig. 3B). Notably, treatment of the transfected cells with CsA
abrogated the differences in luciferase activity induced by the two
alleles, thus suggesting that the effects of the rs2275913 SNP on
the regulation of the IL-17 promoter function are dependent on T
cell activation.
The 197A allele has a stronger interaction with NFAT
than the 197G allele
To substantiate the functional relevance of the rs2275913 SNP,
an EMSA assay was performed. Oligomers containing the 197A or
197G variants were biotin-labeled and allowed to interact with
nuclear extracts derived from PHA-PBMCs. Despite the fact that
the probes differed in just one nucleotide (A/G), the shift band
corresponding to 197A probe-protein complexes was significantly
more intense than that corresponding to 197G probe-protein
complexes (Fig. 4B), thus suggesting that the two alleles have
different affinities for some transcription factor in the nuclear
extracts. A 50-fold excess of unlabeled IL-17 probes abrogated the
formation of DNA-protein complexes, confirming the specificity of
these interactions. Since NFAT has been demonstrated to play a
crucial role in the regulation of IL-17 production [21] and the
rs2275913 SNP maps to within the NFAT binding motif (Fig. 4A),
DNA-protein interactions were subsequently carried out using
recombinant NFAT instead of the nuclear extracts. The 197A
probe-NFAT complexes displayed more a intense band than
197G probe-NFAT complexes (Figs. 4C, D), which were both
completely eliminated by adding a competitor with a 50-fold
excess of unlabeled IL-17 probes or an oligonucleotide containing
a known NFAT target consensus in the binding reaction, thus
suggesting that NFAT is the transcription factor which binds with
differential affinities to the IL-17 probes.
Discussion
The present study showed that the 197A allele of the IL-17 gene
in the donors was associated with a higher risk of acute GVHD
after unrelated fully HLA-matched BMT through the JMDP. The
reason that this association did not significantly influence the
TRM and OS might have resulted from the low incidence of acute
GVHD-related mortality, regardless of the donor IL-17 genotype
in the present cohort. Of note we have found that 197A allele
positive PBMCs can produce IL-17 more efficiently than 197A
allele negative PBMCs, which has not been reported so far, thus
implying that the high inducibility of IL-17 might be correlated
with the development of acute GVHD.
The role of IL-17 in the pathogenesis of acute GVHD remains
unclear. In several mouse model experiments transfer of IL-17
producing cells induced acute GVHD [15,16,17], while in contrast
there is a report [13] showing that donor IL-17 producing cells
ameliorated acute GVHD. Host dendritic cells (DCs) are critical in
the initiation of acute GVHD [39,40,41], thus leading to a
hypothesis that IL-17 producing cells could modify the function of
host DCs through unknown mechanisms. Direct interaction
between IL-17 and host DCs may be supported by the fact that
DCs expressed IL-17 receptors [1].
The IL-17 197A allele, which was associated with the higher
production of IL-17 in comparison with the 197G allele, exhibited a
higher promoter activity, as well as a higher affinity to transcrip-
tional factor NFAT. The functional relevance of rs2275913 SNP
was supported by the findings in our gene reporter assay showing
that the higher promoter activity induced by 197A allele was
stronger in the presence of T cell receptor activation by anti-CD3
and anti-CD28 treatment which is an upstream event in NFAT
induction whereas in conditions leading to NFAT inactivation,
namely CsA treatment, the differences in promoter activity induced
by the 197A and 197G constructs were completely abrogated.
Consistent with these observations, EMSA assay using recombinant
NFAT proteins directly demonstrated a higher in affinity of 197A
Table 4. The results of the multivariate analysis of the association of IL-17 polymorphisms with the GVHD after transplantation.
II–IV acute GVHD Chronic GVHD
Variable Adjusted HR 95% CI P Adjusted HR 95% CI P
Recipient IL-17 genotype, A/G or A/A 0.80 0.56–1.13 0.20 1.32 0.86–1.03 0.21
Donor IL-17 genotype, A/G or A/A 1.46 1.00–2.13 0.05 1.08 0.70–1.67 0.72
doi:10.1371/journal.pone.0026229.t004
Table 5. The results of the multivariate analysis of the association of IL-17 polymorphisms with the clinical outcomes after
transplantation.
OS TRM Relapse
Variable Adjusted HR 95% CI P Adjusted HR 95% CI P Adjusted HR 95% CI P
Recipient IL-17 genotype, A/G or A/A 1.01 0.71–1.42 0.97 1.43 0.84–2.41 0.87 0.75 0.49–1.16 0.19
Donor IL-17 genotype, A/G or A/A 1.29 0.90–1.84 0.16 1.31 0.75–2.31 0.34 1.24 0.79–1.93 0.35
doi:10.1371/journal.pone.0026229.t005
Functional IL-17 Polymorphism in Unrelated BMT
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26229allele. NFAT is a transcription factor crucial for the regulation of T
cell-mediated IL-17 gene transcription [21], and the rs2275913
SNP is located in the promoter adjacent to the NFAT binding
region (Fig. 4A). These findings suggest that the rs2275913 SNP
plays a functional role in the promoter activity of the IL-17 gene
through influencing the transcriptional activity of NFAT, affecting
the production of IL-17 from T cells.
Previous studies have reported an association between the
G197A SNP in the IL-17 promoter region and the susceptibility of
the Japanese population to ulcerative colitis [19], as well as to
rheumatoid arthritis in the Caucasian population [18]. The
present study demonstrated that the 197A genotype is related to
high IL-17 production, and the results of a previous Japanese study
[19] showed that the 197A genotype was a risk factor for the
Figure 2. The influence of the IL-17 SNP on IL-17 secretion by in vitro stimulated PBMCs. (A) PBMCs from healthy individuals were
stimulated for 48 hours in the presence of PHA or in 48 well plates coated with anti-CD3 and anti-CD28 mAbs. The values are expressed as the means
+/2 SD. (B) PBMCs from healthy donors (197A allele positive, n=12 and 197A allele negative, n=10) were cultured for 24 hrs in the presence of PHA.
Total RNA was extracted, and the IL-17 mRNA levels were determined by quantitative RT-PCR and normalized to GAPDH. The data are the means
+/2SD of triplicate measurements in each donor. *indicates P,0.05 and **P,0.01.
doi:10.1371/journal.pone.0026229.g002
Figure 3. The modulation of the reporter gene expression by the rs2275913 SNP. (A) PHA-PBMCs were transfected with a luciferase
expression vector alone (pGL3-Luc) or with a luciferase expression vector containing fragments of the IL-17 promoter with the 197A or 197G alleles
(IL-17/A-Luc and IL-17/G-Luc). The transfected cells were cultured for 48 hr, and firefly luciferase activities were measured and normalized to Renilla
luciferase. (B) The PHA-PBMCs were transfected as described above. Twenty four hours after transfection, the cells were treated with anti-CD3 and
anti-CD28 mAbs or with CsA, and cultured for other 24 hr. The firefly luciferase activities were measured and normalized to Renilla luciferase. The
values represent the normalized levels +/2 S.E.M. from five independent experiments. *indicates P,0.05 and **P,0.01.
doi:10.1371/journal.pone.0026229.g003
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explain the previous observations of increased expression of IL-17
in patients with inflammatory bowel disease such as ulcerative
colitis, which promotes the recruitment of inflammatory cells into
the intestinal mucosa through an increase in chemoattractants and
the expression of adhesion molecules [4,42,43,44]. However,
another study from Norway [18] suggested an association between
the 197A genotype and resistance to developing rheumatoid
arthritis Since many studies have demonstrated higher levels of IL-
17 in patients with rheumatoid arthritis and the essential roles of
IL-17 in mediating joint damage [45,46,47], the G197A SNP
might affect the initiation of rheumatoid arthritis, but not disease
progression and severity. This issue should thus be clarified using
larger cohort studies in the future.
Our earlier report [34] showed an association with the IL-17
197A genotype in the recipient, but not the donor, as in the
present study, with a higher incidence of acute graft-versus-host
disease. However, unlike in the previous study [34], the current
cohort mainly consisted of patients receiving relatively recent
transplants, including reduced-intensity transplantation. The
reason for these discrepancies is unclear, because the year of the
transplant and conditioning intensity were considered as co-factors
in the multivariate analysis. This issue should be clarified by
further investigations in patients at higher risk for acute GVHD,
including those receiving peripheral blood stem cell or HLA-
mismatched transplants.
In conclusion, we have reported that the G197A SNP in the
IL-17 promoter predicts the development of acute GVHD and
plays a functionally important role in the regulation of IL-17
production. Given that the 197A allele is significantly associated
with the higher production of IL-17, G197A genotyping may be
used to predict the susceptibility and severity of other IL-17-
related diseases and complications including rheumatoid arthritis,
periodontal disease, multiple sclerosis, allergic rhinitis, psoriasis,
inflammatory bowel disease, and organ allograft rejection [11].
Furthermore, a better understanding of the molecular mechanism
by which this promoter SNP controls the production of IL-17 may
therefore offer some novel therapeutic insights into the mecha-
nisms of such diseases.
Acknowledgments
We thank all of the Japan Marrow Donor Program (JMDP) transplant
teams who have contributed patients and donors to this study. We are
indebted to Dr. Shoichiro Miyatake at the Tokyo Metropolitan Institute of
Medical Science for providing the plasmid encoding GST-NFAT.
Author Contributions
Conceived and designed the experiments: JLE AT. Performed the
experiments: JLE KN. Analyzed the data: AT. Contributed reagents/
materials/analysis tools: AT MO HA KM YM TF YK SN TK. Wrote the
paper: AT JLE.
Figure 4. The rs2275913 SNP results in differential binding of NFAT. (A) The location of the rs2275913 SNP within the promoter region of
the IL-17 gene. The underlined sequence corresponds to the oligomers used in EMSA assay. The NFAT binding sites [21] are indicated in red and by
red boxes. (B) IL-17 probes were allowed to interact with nuclear extracts from PHA-PBMCs in an EMSA assay. Lane 1, free probes; lane 2, biotin-
labeled probes plus nuclear extracts; lane 3, biotin-labeled probes plus nuclear extracts plus a 50-fold molar excess of unlabeled probes. The figure
shown is representative of five independent experiments. (C) IL-17 probes were allowed to interact with recombinant NFAT proteins in an EMSA
assay. Lane 1, free probes; lane 2, biotin-labeled probes plus GST-NFAT; lane 3, biotin-labeled probes plus GST-NFAT plus a 50-fold molar excess of
unlabeled probes; lane 4, biotin-labeled probes plus GST-NFAT plus a 50-fold molar excess of unlabeled oligomers containing a NFAT consensus site.
The figure shown is representative of five independent experiments. (D) The intensity of the bands corresponding to the DNA/protein interaction
(lane 2 in Fig. 4C) were evaluated by densitometry to compare the binding affinity of the 197A allele and 197G allele for recombinant NFAT. The
values are represented as arbitrary units (au). **indicates P,0.01.
doi:10.1371/journal.pone.0026229.g004
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